• Pediatrics / Neuro-Oncology
• Surgery / Neurosurgery

Address:
DUMC 3624
Durham, NC 27710

Appointment Telephone:
919-668-6288

Office Telephone:
919-684-3506

Fax Telephone:
919-668-2485

• MB BS, Stanley Medical College (India), 1982

• Pediatrics, Lebonheur Children's Medical Center (Tennessee), 1992-1993

• Pediatric Hematology-Oncology, St. Jude Children's Research Hospital (Tennessee), 1991-1992
• Pediatric Hematology-Oncology, Memorial Sloan-Kettering Cancer Center (New York), 1996-1999

• Member (Pediatrics), Royal College of Physicians (England), 1988

Clinical Interests:
Developing innovative phase I and II trials in the treatment of children with recurrent brain tumors

Research Interests:
Dr. Gururangan is a member of the Duke University Medical Center Pediatric Neuro-Oncology program. His current research interest focuses on finding novel chemotherapeutic strategies for the treatment of children and young adults with brain tumors. Since beginning his tenure at the Brain Tumor Center at Duke, he has written seven clinical protocols. These protocols have incorporated some of the important laboratory findings obtained from the laboratory of Dr. Henry Friedman. These protocols are designed to improve survival of children and young adults with brain stem gliomas and other malignant brain tumors. These protocols will be administered locally and in other prominent brain tumor centers around the country that are part of the Pediatric Brain Tumor Consortium.  Dr. Gururangan is the subsite principal investigator for another multi-institutional phase III study of upfront radiation therapy followed dose intensive chemotherapy plus stem cell rescue in children with newly diagnosed medulloblastoma, other PNETs, and ATRT. This study originates at St. Jude Children's Research Hospital, Memphis, TN. The Preston Robert Tisch Brain Tumor Center also has a broad-based agreement with the same institution for broad-based collaboration for clinical trials that originate at Duke or St. Jude Children's Hospital. Dr. Gururangan is the Principal Investigator for Duke in the Pediatric Brain Tumor Consortium sponsored by the National Cancer Institute. He has completed and published two phase I studies through this consortium involving novel alkylating agents in children with recurrent brain tumors. He is currently the chair of an ongoing large phase II study of Bevacizumab plus irinotecan in children with recurrent malignant glioma, diffuse brain stem glioma, medulloblastoma, ependymoma, and low grade gliomas that is also managed through the consortium. Dr. Gururangan is a member of the Duke Brain Tumor SPORE program and the Children's Oncology Group.  Also, through his close ties with an elite group of basic and translational scientists at Duke, he is involved in developing immunology based therapies for children with brain tumors. As a member of these mutliple intramural and extramural groups he is in a strategic position to evaluate novel therapeutic modalities in patients with brain tumors and conduct other  phase I and II clinical trials in children with brain tumors.

Representative Publications:
Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol. 2002 Apr;4(2):102-8. (2002) Abstract

Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 1;20(9):2277-83. (2002) Abstract

Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951-8. (2002) Abstract

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol. 2001 Oct;3(4):246-50. (2001) Abstract

Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol. 2000 May;18(10):2017-25. (2000) Abstract

Gururangan S, Gardner S, and Finlay JL. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for malignant tumors of the central nervous system. Clinical Bone Marrow and Stem Cell Transplantation, 2nd edition, Kerry Atkinson ed., Cambridge University Press, (in press 2000) (2000)

Gururangan S, McFarland JG, Cines DB, Skupski D, Bussel JB. BRa (HPA-5b) incompatibility may cause thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1998 May-Jun;20(3):202-6. (1998) Abstract

Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, Rao BN, Kun LE, Meyer WH. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):55-61. (1998) Abstract

Gururangan S, Dunkel IJ, Goldman S, Garvin J, Rosenblum M, Boyett J, and Finlay J. Myeloablative chemotherapy followed by autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16 (7): 2486-2493 (1998)